22 May 2013
Keywords: ralfinamide, enters, ph, iib/iii, study, nlbp, italy
Article | 01 April 2009
Italy's Newron Pharmaceuticals SpA has randomized the first patients to treatment in its first Phase IIb/III study of ralfinamide ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 April 2009
31 March 2009
21 May 2013
© 2013 thepharmaletter.com